IO Ivanikov, ME Brekhova, GE Samonina, NF Myasoedov, IP Ashmarin: Therapy of peptic ulcer with semax peptide. In: Bulletin of experimental biology and medicine. 134. Jahrgang, Nr.1, 2002, S.73–4, doi:10.1023/A:1020621124776, PMID 12459874.
O. V. Dolotov, E. A. Karpenko, L. S. Inozemtseva et al.: Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. In: Brain Res. 1117. Jahrgang, Nr.1, Oktober 2006, S.54–60, doi:10.1016/j.brainres.2006.07.108, PMID 16996037.
K. O. Eremin, V. S. Kudrin, P. Saransaari et al.: Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. In: Neurochem. Res. 30. Jahrgang, Nr.12, Dezember 2005, S.1493–1500, doi:10.1007/s11064-005-8826-8, PMID 16362768.
K. A. Yatsenko, N. Y. Glazova, L. S. Inozemtseva et al.: Heptapeptide semax attenuates the effects of chronic unpredictable stress in rats. In: Dokl. Biol. Sci. 453. Jahrgang, November 2013, S.353–357, doi:10.1134/S0012496613060161, PMID 24385169.
S. J. Tsai: Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. In: Med. Hypotheses. 68. Jahrgang, Nr.5, 2007, S.1144–1146, doi:10.1016/j.mehy.2006.07.017, PMID 16996699.
nih.gov
ncbi.nlm.nih.gov
NI Kurysheva, AA Shpak, EE Ioĭleva, LI Galanter, ND Nagornova, NIu Shubina, NN Shlyshalova: Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone. In: Vestnik oftalmologii. 117. Jahrgang, Nr.4, 2001, S.5–8, PMID 11569188.
IO Ivanikov, ME Brekhova, GE Samonina, NF Myasoedov, IP Ashmarin: Therapy of peptic ulcer with semax peptide. In: Bulletin of experimental biology and medicine. 134. Jahrgang, Nr.1, 2002, S.73–4, doi:10.1023/A:1020621124776, PMID 12459874.
O. V. Dolotov, E. A. Karpenko, L. S. Inozemtseva et al.: Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. In: Brain Res. 1117. Jahrgang, Nr.1, Oktober 2006, S.54–60, doi:10.1016/j.brainres.2006.07.108, PMID 16996037.
K. O. Eremin, V. S. Kudrin, I. A. Grivennikov, N. F. Miasoedov, K. S. Rayevsky: Effects of Semax on dopaminergic and serotoninergic systems of the brain. In: Dokl. Biol. Sci. 394. Jahrgang, 2004, S.1–3, PMID 15088389.
K. O. Eremin, V. S. Kudrin, P. Saransaari et al.: Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. In: Neurochem. Res. 30. Jahrgang, Nr.12, Dezember 2005, S.1493–1500, doi:10.1007/s11064-005-8826-8, PMID 16362768.
D. A. Vilenskiĭ, N. G. Levitskaia, L. A. Andreeva, L. I. Alfeevau, A. A. Kamenskiĭ, N. F. Miasoedov: [Effects of chronic Semax administration on exploratory activity and emotional reaction in white rats]. In: Ross Fiziol Zh Im I M Sechenova. 93. Jahrgang, Nr.6, Juni 2007, S.661–9, PMID 17850024 (russisch).
K. A. Yatsenko, N. Y. Glazova, L. S. Inozemtseva et al.: Heptapeptide semax attenuates the effects of chronic unpredictable stress in rats. In: Dokl. Biol. Sci. 453. Jahrgang, November 2013, S.353–357, doi:10.1134/S0012496613060161, PMID 24385169.
M. A. Volodina, E. A. Sebentsova, N. Y. Glazova et al.: Semax attenuates the influence of neonatal maternal deprivation on the behavior of adolescent white rats. In: Bull. Exp. Biol. Med. 152. Jahrgang, Nr.5, März 2012, S.560–3, PMID 22803132.
Pae CU: Therapeutic possibility of "Semax" for depression. In: CNS Spectr. 13. Jahrgang, Nr.1, Januar 2008, S.20–21, PMID 18204410.
S. J. Tsai: Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. In: Med. Hypotheses. 68. Jahrgang, Nr.5, 2007, S.1144–1146, doi:10.1016/j.mehy.2006.07.017, PMID 16996699.
N. V. Kost, O. I. Sokolovu, M. V. Gabaeva et al.: Semax and selank inhibit the enkephalin-degrading enzymes from human serum. In: Bioorg. Khim. 27. Jahrgang, Nr.3, 2001, S.180–183, PMID 11443939 (russisch).
